OncoVista Innovative Therapies has requested a meeting with the FDA to discuss an investigational device exemption for its AdnaTest Breast Cancer device. The company expects to reach an agreement with the agency on the design and review criteria for a study that will be used for its product approval application, CEO Alexander L. Weis said.

Related Summaries